Table 1.
Clinical Characteristics of the Enrolled Patients
| Characteristics | Total (n=1,137) | 7d-TT (n=377) | 10d-CT (n=383) | 10d-ST (n=377) | p-value |
|---|---|---|---|---|---|
| Age, yr | 0.51* | ||||
| Mean±SD | 55.0±11.4 | 55.8±10.7 | 54.9±11.7 | 54.4±11.7 | |
| Median (range) | 56 (22–84) | 56 (27–79) | 56 (23–80) | 56 (22–84) | |
| Sex | 0.87† | ||||
| Male | 621 (54.6) | 208 (55.1) | 205 (53.5) | 208 (55.1) | |
| Female | 516 (45.3) | 169 (44.8) | 178 (46.4) | 169 (44.8) | |
| Smoking | 0.70† | ||||
| Never smoker | 729 (64.1) | 234 (62.0) | 254 (66.3) | 241 (63.9) | |
| Ex-smoker | 197 (17.3) | 70 (18.5) | 65 (16.9) | 62 (16.4) | |
| Current smoker | 211 (18.5) | 73 (19.3) | 64 (16.7) | 74 (19.6) | |
| Alcohol consumption | 0.61† | ||||
| Never drinker | 468 (41.1) | 150 (39.7) | 154 (40.2) | 164 (43.5) | |
| Ex-drinker | 118 (10.3) | 45 (11.9) | 40 (10.4) | 33 (8.7) | |
| Current drinker | 551 (48.4) | 182 (48.2) | 189 (49.3) | 180 (47.7) | |
| General medical history‡ | 498 (43.8) | 172 (45.6) | 160 (41.7) | 166 (44.0) | 0.56† |
| Past medical history of GI diseases§ | 840 (73.8) | 284 (75.3) | 280 (73.1) | 276 (73.2) | 0.73† |
| Family history of gastric cancer | 154 (13.5) | 58 (15.3) | 51 (13.3) | 45 (11.9) | 0.37† |
| Benign gastric ulcer | 183 (16.0) | 67 (17.7) | 56 (14.6) | 60 (15.9) | 0.49† |
| Benign duodenal ulcer | 132 (11.6) | 39 (10.3) | 43 (11.2) | 50 (13.2) | 0.43† |
| After ESD for EGC | 79 (6.9) | 32 (8.4) | 26 (6.7) | 21 (5.5) | 0.28† |
| MALT lymphoma | 6 (0.5) | 2 (0.5) | 1 (0.2) | 3 (0.3) | 0.54* |
| Atrophic or metaplastic gastritis | 606 (53.3) | 212 (56.2) | 197 (51.4) | 197 (52.2) | 0.36† |
| Gastric adenoma | 72 (6.3) | 21 (5.5) | 28 (7.3) | 23 (6.1) | 0.60† |
| Gastric polypII | 66 (5.8) | 15 (3.9) | 22 (5.7) | 29 (7.6) | 0.09† |
| Iron deficiency anemia | 2 (0.1) | 1 (0.2) | 1 (0.2) | - | 1.00* |
| Helicobacter pylori (+) gastritis | 381 (33.5) | 116 (30.7) | 128 (33.4) | 137 (36.3) | 0.26† |
Data are presented as number (%).
7d, 7 days; TT, triple therapy; CT, concomitant therapy; ST, sequential therapy; GI, gastrointestinal; ESD, endoscopic submucosal dissection; EGC, early gastric cancer; MALT, mucosa-associated lymphoid tissue.
Fisher exact test;
Chi-square test;
General medical history includes hypertension, arrhythmia, myocardial infarction, heart failure, diabetes mellitus, asthma, chronic obstructive pulmonary disease, liver cirrhosis, renal failure, and any cancer except GI cancer;
Past medical history of GI diseases includes esophagitis, gastric ulcer, duodenal ulcer, gastric cancer, past history of abdominal surgery, gastrectomy, intractable iron deficiency anemia, chronic idiopathic thrombocytopenic purpura, atrophic gastritis, and nonulcer dyspepsia;
Gastric polyp includes hyperplastic and inflammatory polyps.